All lobbying filings

TIBER CREEK GROUP

Lobbying for ALNYLAM PHARMACEUTICALS, INC. · Biopharmaceuticals.

Filing Q1 report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 17, 2026

Income

$60,000.00

What the client paid this registrant for the period.

Client based in

Massachusetts

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Bills named in this filing 3

HR 946
ORPHAN Cures Act
S 1862
ORPHAN Cures Act
HR 1672
Maintaining Investments in New Innovation Act

Lobbying activity 1

Medicare/Medicaid

Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.